Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
Affiliations
- PMID: 32870807
- DOI: 10.1515/dmpt-2019-0033
Abstract
Objectives Although pharmacogenetic tests provide the information on a genotype and the predicted phenotype, these tests do not themselves provide the interpretation of data for a physician. Currently, there are approximately two dozen pharmacogenomic clinical decision support systems (CDSSs) used in psychiatry. Implementation of the CDSSs forming the recommendations on drug and dose selection according to the results of pharmacogenetic testing is an urgent task. Fulfillment of this task will allow increasing the efficacy of therapy and decreasing the risk of undesirable side effects. Methods The study included 118 male patients (48 in the main group and 70 in the control group) with affective disorders and comorbid alcohol use disorder. To evaluate the efficacy and safety of therapy, several international psychometric scales and rating scales to measure side effects were used. Genotyping was performed using the real-time polymerase chain reaction with allele-specific hybridization. Pharmacogenetic testing results were interpreted using free software PGX2 (LLE Medicine, Russian Federation, Biomedical Cluster of Skolkovo, Moscow Innovative Cluster; www.pgx2.com). Results The statistically significant differences across the scores on psychometric scales were revealed. For instance, the total score on the Hamilton Rating Scale for Depression by day 9 was 9.0 [8.0; 10.0] for the main group and 11.0 [10.0; 12.0] (p<0.001) for the control group and by day 16 it was 4.0 [2.0; 6.0] for the main group and 14.0 [13.0; 14.0] (p<0.001) for the control group. The UKU Side-Effect Rating Scale (UKU) also revealed a statistically significant difference. The total score on the UKU scale by day 9 was 4.0 [4.0; 5.0] for the main group and 5.0 [5.0; 6.0] (p<0.001) for the control group and by day 16 this difference grew significantly: 3.0 [0.0; 4.2] for the main group and 9.0 [7.0; 11.0] (p<0.001) for the control group. Conclusions Pharmacogenetic-guided personalization of the drug dose in patients with affective disorders and comorbid alcohol use disorder can reduce the risk of undesirable side effects and pharmacoresistance. It allows recommending the use of pharmacogenetic CDSSs for optimizing drug dosage.
Keywords: clinical decision support system; fluvoxamine; personalized medicine; pharmacogenetics.
Similar articles
- Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25.PMID: 30357930
- Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.Pharmgenomics Pers Med. 2018 Jun 29;11:113-119. doi: 10.2147/PGPM.S160763. eCollection 2018.PMID: 29988737 Free PMC article.
- Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.Gene. 2020 May 20;739:144513. doi: 10.1016/j.gene.2020.144513. Epub 2020 Feb 26.PMID: 32112986
- Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338.PMID: 28385173 Review.
- [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].Dtsch Med Wochenschr. 2016 Oct;141(21):e183-e202. doi: 10.1055/s-0042-100973. Epub 2016 Oct 17.PMID: 27750332 Review. German.
No hay comentarios:
Publicar un comentario